VRX – Valeant Pharmaceuticals International, Inc – a specialty pharmaceutical and medical device company, is famous for its growth by acquisition strategy. It fell 18% on 29th Feb 2016.
|VRX – Valeant Pharmaceuticals International, Inc|
|Fundamentals||Previously closed at||65.8|
|Analysts opinion||VRX has a PEG ratio of 0.37, P/S ratio of 2.77, and a P/B ratio of 4.36. It has a forward PE of 4.91. Valeant’s CEO Micheal Pearson returned after an indefinate medical leave. VRX postponed the release of its Q4 earnings results and completely withdrew its 2016 guidance. Due to these, the stock price plummetted more than 18% on monday.|
|Sentiments||Post this, many brokers either lowered their price objectives or downgraded the stocks. Deutsche Bank suspended the coverage on the stock. Due to this, the stock may have further bearish sentiments today.|
|However, Janus Capital Management raised its stakes in VRX during the 3rd quarter last year, which indicates that hedge funds have faith in the business model of the company.|
|Revenue Prediction||The Estimize consensus revenue for VRX is $2.8 billion|
|Social Pulse||The stock has 1% lower social chatter than usual.|